Our team ‘brings it’ every day for one mission: to conquer transcription factors and create cutting-edge medicines for patients.

Flare is lighting up a new therapeutic space with an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of our scientific founders, Flare’s team is leveraging the power of ‘switch sites’ as druggable regions that hold the control for predictable and profound changes in DNA transcription, and therefore, gene expression. Our drug discovery to target ‘switch sites’ has rapidly advanced, resulting in our pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology.

Eventide

Boxer Capital

Casdin Capital

Nextech Invest

Invus

Third Rock Ventures

Flare Therapeutics

May is Bladder Cancer Awareness Month. To help raise awareness and honor those who have been impacted by the disease, the Flare team participated in the Bladder Cancer Advocacy Network's Boston Walk to End Bladder Cancer this past weekend. Thank you to our friends at BCAN for organizing a great event and for recognizing Flare with an award for the largest team, with more than 20 walkers. #bladdercancermonth23

We are excited to share that Flare Therapeutics is one of Inc. Magazine's Best Workplaces of 2023! Trailblazing a path to the possible for patients while cultivating a positive and collaborative work environment is part of what makes Flare so special. We are honored to be recognized. Check us out! flaretx.com #IncBestWorkplaces

The Flare team traveled to the recent #aacr2023 annual meeting in Orlando, Florida, putting FX-909 on full display with not one but two presentations from Jennifer Mertz, VP, Biology, shown below in front of a poster of our first preclinical data for FX-909, and CSO Robert Sims, shown presenting Flare's discovery of this first-in-class inhibitor of the #pparg transcription factor to potentially treat individuals with advanced urothelial cancer. Way to go, team! https://lnkd.in/eUB7ETQs

Flare continues to grow, and we're not stopping! We are glad to welcome Phuong Anh (Ani) Nguyen, Jon Goldstein, Blanche Carroll, and Mike Aguiar as the newest members of our team. To see other open roles at Flare, please visit flaretx.com/join-us/ #bringyourflare #team

This week, Flare Therapeutics announced the fantastic news that Michael Meyers has been appointed Chief Medical Officer, Daphne Karydas has been promoted to President, and Michaela Bowden has been promoted to Chief Development Officer. “Our commitment to strengthening our team reflects the tremendous progress we have made to date and the pivotal year ahead of us as we transition into a clinical-stage company,” said CEO Amit Rakhit, MD, MBA. #bringyourflare

https://lnkd.in/e-XttY_p

The Flare team is honored to announce our oversubscribed Series B financing co-led by GordonMD® Global Investments LP and Pfizer Ventures LLC, with participation from a world-class group of existing and new investors. Proceeds from our financing will #illuminatethepath to a clinical trial in 2023 for FX-909, a small molecule inhibitor targeting the PPARG transcription factor, in patients with advanced #urothelialcancer, as well as the advancement of a pipeline of novel transcription factor targets in oncology, including nomination of at least one additional development candidate from the company’s research pipeline in 2024.
 
We are immensely grateful to the Flare team for continuing to trailblaze a path to the possible for science and patients. Our team ‘brings it’ every day for one mission: to conquer transcription factors and create cutting-edge medicines. #seriesbfinancing #lifescienceinvestment #transcriptionfactors #pparg #oncology

Agent Capital Boxer Capital, LLC Casdin Capital, LLC Eli Lilly and Company Eventide Asset Management INVUS FINANCIAL ADVISORS, LLC Memorial Sloan Kettering Cancer Center Nextech Invest Novartis Pavilion Capital ShangBay Capital Third Rock Ventures

https://lnkd.in/ehBZiizY

This Thursday, Daphne Karydas, Flare CFO and COO, will give a company overview and answer questions at the 34th Annual @PiperSandler Healthcare Conference in New York. If you are attending, join her at 9:30am ET on December 1st. #PSCHealthcare2022

Check out this excellent story in Precision Oncology News profiling Flare Therapeutics' work building a potential new approach to targeting and treating advanced #urothelialcancers by inhibiting the #transcriptionfactor #PPARG. Robert Sims and Michaela Bowden spoke with Catherine Shaffer about the significance of our preclinical and translational research, as well as plans to enter the clinic in 2023. Read the story here: https://lnkd.in/eEEme8zm
#OneFlare #CancerResearch
#PrecisionOncology #IlluminatethePath

Over the past few months, we have added quite a few new sparks to flame our collective fire. We are certainly shining brightly as we look toward 2023. To Dave Lanzetta Melissa Moles Jeremy Setser Ana Rivas Stefan Kirov Serena Lunardi Jennifer Tepper Esin Tosun, welcome to Flare! #bebrilliant #oneflare

Flare Therapeutics is a biotechnology research company based in Cambridge, MA. They are trailblazing the path to target transcription factors and discover precision medicines for cancer and other disease areas. Their unique approach involves deciphering the biology of transcription factors by focusing on 'switch sites' as druggable regions that control predictable and profound changes in DNA transcription and gene expression. They have a pipeline of drug programs initially focused on precision oncology.

COM:FLARETX

Flare Therapeutics

Filings Not Available